Medicare annual enrollment

Eligible U.S. residents can apply for and make changes to their Medicare plans from October 15 – December 7. Medicare is a health insurance plan for people ages 65 and up, or those with certain conditions or disabilities. It is important to know your options and pick a plan that lets you keep your ARC care team.

Tips for patients

COVID-19 vaccine appointments available for ages 6 months+

Scheduling for COVID-19 vaccine appointments for ages 6 months+ is now available:

Flu shots available

Scheduling for ARC flu clinics is now available. It's easy to get your flu shot:

MyChart Login Help Me Book

VAX 31-201 Pediatric Pneumococcal Clinical Study

Austin Regional Clinic physicians constantly work to improve the care given to all our patients. We are dedicated to offering unique options for our patients and helping them reach their ideal health goals. Part of this dedication involves making clinical research available. Clinical research makes it possible to discover the benefits, risks, and safety of commercially available and investigational medications.

Research standards are very strict to help make studies as safe as possible. Teams of government and research experts have already reviewed each study we conduct to minimize any study risks. Austin Regional Clinic has decided to be involved in this research study because we believe it can potentially benefit our patients.

About the VAX 31-201 pediatric pneumococcal clinical study

A phase II, randomized-double, active-controlled, dose-finding clinical study to evaluate the safety, tolerability, and immunogenicity of VAX-31 in healthy infants given four doses at two, four, six, and 12-15 months of age concomitantly with routine pediatric vaccines.

By participating in this study, you would be contributing to the development of groundbreaking technology with the potential to benefit many people in the future. ARC is one of the many study centers in the United States participating in this research study.

What to expect

We are currently seeking candidates for a clinical research study. During the study, patients can expect:

  • The duration may be up to 21 months
  • The study vaccine (Vax-31 or PCV 20 pneumococcal conjugate vaccine) will be given at two, four, six, and 12-15 months of age
  • Participants will receive the routine Advisory Committee on Immunization Practices recommended vaccine regimen concomitantly with all four doses of study vaccine

Eligibility criteria

All participants must:

  • Be a healthy male or female between the ages of 42 and 89 days

Location

Request to participate

Please contact our ARC Clinical Research team to request to participate by calling 737-247-7240.